Clinical Trial Update: Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating durvalumab with or without olaparib as maintenance therapy after first-line treatment for advanced or recurrent endometrial cancer, wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer

Drugs mentioned

• Durvalumab (durvalumab)
• Olaparib (Olaparib)

Snippet

Sponsor: AstraZeneca | Conditions: Endometrial Neoplasms | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-12-23